165 related articles for article (PubMed ID: 33079424)
1. Plerixafor-based mobilization in pediatric healthy donors with unfavorable donor/recipient body weight ratio resulted in a better CD34
Zubicaray J; Galvez E; Sebastian E; Molina B; González-Vicent M; Castillo A; Ramírez M; Madero L; Díaz MA; Sevilla J
J Clin Apher; 2021 Feb; 36(1):78-86. PubMed ID: 33079424
[TBL] [Abstract][Full Text] [Related]
2. Plerixafor added to G-CSF allows mobilization of a sufficient number of hematopoietic progenitors without impacting the efficacy of TCR-alpha/beta depletion in pediatric haploidentical and genoidentical donors failing to mobilize with G-CSF alone.
Kurnikova E; Trakhtman P; Pershin D; Ilyushina M; Khismatullina R; Maschan M; Novichkova G; Maschan A
J Clin Apher; 2021 Aug; 36(4):547-552. PubMed ID: 33682959
[TBL] [Abstract][Full Text] [Related]
3. Addition of plerixafor to G-CSF in poor mobilizing healthy related donors overcame mobilization failure: An observational case series on behalf of the Grupo Español de Trasplante Hematopoyético (GETH).
Cid J; Monsalvo S; Castillo C; Pascual C; Moreno-Jiménez G; López-Parra M; Andón C; Guerra L; Esquirol A; Sánchez-Ortega I; Ortega S; Zalba S; Martínez C; Rovira M; Marín P; Lozano M;
Transfus Apher Sci; 2021 Apr; 60(2):103052. PubMed ID: 33483284
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of a reduced dose of plerixafor in combination with granulocyte colony-stimulating factor in healthy haploidentical stem cell donors.
Kurnikova E; Trakhtman P; Balashov D; Garloeva J; Kumukova I; Khismatullina R; Pershin D; Shelikhova L; Novichkova G; Maschan A
Vox Sang; 2022 Jun; 117(6):853-861. PubMed ID: 35332550
[TBL] [Abstract][Full Text] [Related]
5. Addition of plerixafor in poorly mobilized allogeneic stem cell donors.
Zhuang L; Lauro D; Wang S; Yuan S
J Clin Apher; 2022 Aug; 37(4):388-394. PubMed ID: 35633513
[TBL] [Abstract][Full Text] [Related]
6. Plerixafor combined with G-CSF for stem cell mobilization in children qualified for autologous transplantation- single center experience.
Malinowska I; Romiszewski M; Smalisz K; Stelmaszczyk-Emmel A; Nasilowska-Adamska B; Krol M; Urbanowska E; Brozyna A; Baginska-Dembowska B
Transfus Apher Sci; 2021 Jun; 60(3):103077. PubMed ID: 33583716
[TBL] [Abstract][Full Text] [Related]
7. [A Single-Center Analysis of the Use of G-CSF Combined with Plerixafor to Mobilize Peripheral Blood Hematopoietic Stem Cell from Healthy Related Donors in Allogeneic Hematopoietic Stem Cell Transplantation].
Chen J; Yuan LL; Zhang X; Qiao JL; Yin QX; Zhang YM; Yang XL; Cao XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):286-291. PubMed ID: 35123641
[TBL] [Abstract][Full Text] [Related]
8. A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: An Italian explorative cost Analysis.
Laszlo D; Marcacci GP; Martino M; Radice D; Rabascio C; Lucchetti B; Magarò A; Caime A; Menna S; Lionetti MT; Bertolini F
Transfus Apher Sci; 2020 Oct; 59(5):102819. PubMed ID: 32499108
[TBL] [Abstract][Full Text] [Related]
9. Factors predicting peripheral blood progenitor cell collection from pediatric donors for allogeneic transplantation.
Díaz MA; Sevilla J; de la Rubia J; Verdeguer A; Espigado I; Vicent MG; Pascual MJ; Zamora C; Arrieta R; Serrano D; del Cañizo C; Arbona C; de Arriba F; Bargay J; Brunet S; Sanz MA
Haematologica; 2003 Aug; 88(8):919-22. PubMed ID: 12935980
[TBL] [Abstract][Full Text] [Related]
10. Engraftment after autologous hematopoietic stem cell transplantation in patients mobilized with Plerixafor: A retrospective, multicenter study of a large series of patients.
Antelo ML; Altuna A; Gimeno JJ; Ferreiro JJ; Amunárriz C; Mateos JJ; Zalba S; Alkorta A; Rifón J; Arroyo JL; Uresandi A; Moreno JA; Nájera MJ; Pinzón S; García A; Vallejo JC;
Transfus Apher Sci; 2021 Jun; 60(3):103130. PubMed ID: 33840626
[TBL] [Abstract][Full Text] [Related]
11. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
[TBL] [Abstract][Full Text] [Related]
12. Stem Cells mobilization and collection in allogeneic related and unrelated donors: a single center experience with focus on plerixafor.
Marcon C; Bertone A; Mauro S; Mestroni R; Battaglia G; Pizzano U; Facchin G; De Martino M; Isola M; Patriarca F; Barillari G; Savignano C
Transfus Apher Sci; 2023 Dec; 62(6):103845. PubMed ID: 37953206
[TBL] [Abstract][Full Text] [Related]
13. Multiple Myeloma: Risk Adapted Use of Plerixafor for Stem Cell Mobilization Prior to Autologous Stem Cell Transplantation is Effective and Cost Efficient.
Prakash VS; Malik PS; Sahoo RK; Pramanik R; Choudhary P; Varshney AN; Kumar L
Clin Lymphoma Myeloma Leuk; 2022 Jan; 22(1):44-51. PubMed ID: 34452863
[TBL] [Abstract][Full Text] [Related]
14. A multicenter report on the safety and efficacy of plerixafor based stem cell mobilization in children with malignant disorders.
Bhunia N; Abu-Arja R; Stanek JR; Mehyar LS; Shaw PJ; Kang HJ; Stein J; O'Brien TA; Roberts CH; Lee AC; Loeb DM; Ozkaynak MF; Dalal JD; Strahlendorf C; Goyal RK; Shenoy SS; Rangarajan HG
Transfusion; 2021 Mar; 61(3):894-902. PubMed ID: 33475172
[TBL] [Abstract][Full Text] [Related]
15. EMA Recommendation for the Pediatric Indications of Plerixafor (Mozobil) to Enhance Mobilization of Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Children with Lymphoma or Malignant Solid Tumors.
Karres D; Ali S; van Hennik PB; Straus S; Josephson F; Thole G; Glerum PJ; Herberts C; Babae N; Herold R; Papadouli I; Pignatti F
Oncologist; 2020 Jun; 25(6):e976-e981. PubMed ID: 32154610
[TBL] [Abstract][Full Text] [Related]
16. The use of plerixafor in hematopoietic progenitor cell collection in pediatric patients: a single center experience.
Pham HP; Patel N; Semedei-Pomales M; Bhatia M; Schwartz J
Cytotherapy; 2012 Apr; 14(4):467-72. PubMed ID: 22339604
[TBL] [Abstract][Full Text] [Related]
17. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.
Pusic I; Jiang SY; Landua S; Uy GL; Rettig MP; Cashen AF; Westervelt P; Vij R; Abboud CN; Stockerl-Goldstein KE; Sempek DS; Smith AL; DiPersio JF
Biol Blood Marrow Transplant; 2008 Sep; 14(9):1045-1056. PubMed ID: 18721768
[TBL] [Abstract][Full Text] [Related]
18. High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection.
Engelhardt M; Bertz H; Afting M; Waller CF; Finke J
J Clin Oncol; 1999 Jul; 17(7):2160-72. PubMed ID: 10561272
[TBL] [Abstract][Full Text] [Related]
19. Optimization of repeat plerixafor dosing for autologous peripheral blood stem-cell collection.
Gupta GK; Perreault S; Seropian SE; Tormey CA; Hendrickson JE
Transfus Apher Sci; 2021 Jun; 60(3):103069. PubMed ID: 33546988
[TBL] [Abstract][Full Text] [Related]
20. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide.
Shaughnessy P; Islas-Ohlmayer M; Murphy J; Hougham M; MacPherson J; Winkler K; Silva M; Steinberg M; Matous J; Selvey S; Maris M; McSweeney PA
Biol Blood Marrow Transplant; 2011 May; 17(5):729-36. PubMed ID: 20813198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
